A Morning Routine to Double Your Money in 13 Minutes?
Wake up. Get coffee. Turn on your computer… In 13 minutes... you could be 98% richer… Go play golf... or tennis... or whatever you like.

It's easy… if you follow a few simple instructions.
Click Here to Learn the Secret >>

CNTA Insider Trading (Centessa Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $464,540.00
Insider Selling (Last 12 Months): $0.00

Centessa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Centessa Pharmaceuticals Share Price & Price History

Current Price: $11.60
Price Change: Price Increase of +0.22 (1.93%)
As of 11/26/2021 01:00 AM ET

This chart shows the closing price history over time for CNTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Next Breakthrough Plant-Based Dairy Company
The growing demand for plant based dairy products may hurl this company to the spotlight.
Continue Reading

Centessa Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Aaron KantoffDirectorBuy10,000$11.98$119,800.00View SEC Filing Icon  
11/16/2021Saurabh SahaCEOBuy23,000$12.28$282,440.00View SEC Filing Icon  
11/16/2021Tia L. BushInsiderBuy5,000$12.46$62,300.00View SEC Filing Icon  
See Full Table
Insider Trading at Centessa Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Centessa Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Centessa Pharmaceuticals (NASDAQ:CNTA)

63.51% of Centessa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Centessa Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Janus Henderson Group PLC5,607,302$91.36M0.0%-1.3%6.237%Search for SEC Filing on Google Icon
11/16/2021Brookfield Asset Management Inc.26,788$0.45M0.0%+45.6%0.030%Search for SEC Filing on Google Icon
11/16/2021Millennium Management LLC337,002$5.63M0.0%-38.6%0.375%Search for SEC Filing on Google Icon
11/16/2021Boxer Capital LLC1,334,227$22.28M0.8%+47.6%1.484%Search for SEC Filing on Google Icon
11/16/2021Citadel Advisors LLC349,548$5.84M0.0%-23.4%0.389%Search for SEC Filing on Google Icon
11/15/2021Point72 Asset Management L.P.302,200$5.05M0.0%+202.2%0.336%Search for SEC Filing on Google Icon
11/15/2021RA Capital Management L.P.3,577,094$59.74M0.8%+179.4%3.979%Search for SEC Filing on Google Icon
11/15/2021Morgan Stanley7,630$0.13M0.0%N/A0.008%Search for SEC Filing on Google Icon
11/15/2021General Atlantic L.P.9,681,818$161.69M0.9%+545.5%10.770%Search for SEC Filing on Google Icon
11/15/2021Ensign Peak Advisors Inc286,404$4.78M0.0%-18.2%0.319%Search for SEC Filing on Google Icon
11/12/2021Affinity Asset Advisors LLC203,183$3.39M0.9%+203.5%0.226%Search for SEC Filing on Google Icon
11/12/2021Ghisallo Capital Management LLC15,000$0.25M0.0%-40.0%0.017%Search for SEC Filing on Google Icon
11/10/2021American Century Companies Inc.370,292$6.18M0.0%-0.3%0.412%Search for SEC Filing on Google Icon
11/9/2021Jennison Associates LLC296,456$4.95M0.0%-1.2%0.330%Search for SEC Filing on Google Icon
10/28/2021Compagnie Lombard Odier SCmA2,750$46K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace North America L.P.34,228$0.76M0.0%N/A0.038%Search for SEC Filing on Google Icon
8/18/2021Blackstone Inc40,000$0.89M0.0%N/A0.044%Search for SEC Filing on Google Icon
8/17/2021Woodline Partners LP822,518$18.27M0.3%N/A0.915%Search for SEC Filing on Google Icon
8/17/2021Samsara BioCapital LLC1,537,533$34.15M4.2%N/A1.710%Search for SEC Filing on Google Icon
8/17/2021Brookfield Asset Management Inc.18,404$0.41M0.0%N/A0.020%Search for SEC Filing on Google Icon
8/17/2021Logos Global Management LP939,545$20.87M1.8%N/A1.045%Search for SEC Filing on Google Icon
8/17/2021Millennium Management LLC548,452$12.18M0.0%N/A0.610%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD2,011,073$43.86M0.0%N/A2.237%Search for SEC Filing on Google Icon
8/17/2021BVF Inc. IL58,900$1.31M0.0%N/A0.066%Search for SEC Filing on Google Icon
8/17/2021Boxer Capital LLC904,227$20.08M0.7%N/A1.006%Search for SEC Filing on Google Icon
8/17/2021Caas Capital Management LP62,500$1.39M0.0%N/A0.070%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC456,233$10.13M0.0%N/A0.507%Search for SEC Filing on Google Icon
8/16/2021Squarepoint Ops LLC37,771$0.84M0.0%N/A0.042%Search for SEC Filing on Google Icon
8/16/2021Bank of America Corp DE2,398$54K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/16/2021Point72 Asset Management L.P.100,000$2.22M0.0%N/A0.111%Search for SEC Filing on Google Icon
8/16/2021Blackstone Inc40,000$0.89M0.0%N/A0.044%Search for SEC Filing on Google Icon
8/16/2021RA Capital Management L.P.1,280,300$28.44M0.5%N/A1.424%Search for SEC Filing on Google Icon
8/16/2021Tudor Investment Corp Et Al43,079$0.96M0.0%N/A0.048%Search for SEC Filing on Google Icon
8/16/2021Avoro Capital Advisors LLC500,000$11.11M0.2%N/A0.556%Search for SEC Filing on Google Icon
8/13/2021General Atlantic L.P.1,500,000$33.32M0.2%N/A1.669%Search for SEC Filing on Google Icon
8/13/2021VR Adviser LLC1,127,272$25.04M3.0%N/A1.254%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp18,400$0.41M0.0%N/A0.020%Search for SEC Filing on Google Icon
8/13/2021Affinity Asset Advisors LLC66,957$1.49M0.5%N/A0.074%Search for SEC Filing on Google Icon
8/13/2021Franklin Resources Inc.922,700$20.49M0.0%N/A1.026%Search for SEC Filing on Google Icon
8/13/2021Ensign Peak Advisors Inc350,000$7.77M0.0%N/A0.389%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC9,513$0.21M0.0%N/A0.011%Search for SEC Filing on Google Icon
8/13/2021FMR LLC790,000$17.55M0.0%N/A0.879%Search for SEC Filing on Google Icon
8/12/2021Vida Ventures Advisors LLC3,931,818$87.33M21.9%N/A4.374%Search for SEC Filing on Google Icon
8/12/2021State of Wisconsin Investment Board80,381$1.79M0.0%N/A0.089%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.2,090$47K0.0%N/A0.002%Search for SEC Filing on Google Icon
8/12/2021Jennison Associates LLC300,000$6.66M0.0%N/A0.334%Search for SEC Filing on Google Icon
8/12/2021Monashee Investment Management LLC130,000$2.89M0.3%N/A0.145%Search for SEC Filing on Google Icon
8/5/2021American Century Companies Inc.371,504$8.25M0.0%N/A0.413%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Centessa Pharmaceuticals logo
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Read More on Centessa Pharmaceuticals

Today's Range

Now: $11.60
Low: $11.08
High: $11.75

50 Day Range

MA: $15.61
Low: $11.38
High: $22.36

52 Week Range

Now: $11.60
Low: $10.71
High: $26.90

Volume

60,500 shs

Average Volume

199,296 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Centessa Pharmaceuticals?

Centessa Pharmaceuticals' top insider shareholders include:
  1. (Bermuda) Ltd Gap (Major Shareholder)
  2. Aaron Kantoff (Director)
  3. Saurabh Saha (CEO)
  4. Tia L Bush (Insider)

Who are the major institutional investors of Centessa Pharmaceuticals?

Centessa Pharmaceuticals' top institutional investors include:
  1. General Atlantic L.P. — 10.77%
  2. Janus Henderson Group PLC — 6.24%
  3. RA Capital Management L.P. — 3.98%
  4. Boxer Capital LLC — 1.48%
  5. American Century Companies Inc. — 0.41%
  6. Citadel Advisors LLC — 0.39%

Which institutional investors are selling Centessa Pharmaceuticals stock?

Within the previous quarter, CNTA stock was sold by these institutional investors:
  1. Millennium Management LLC
  2. Citadel Advisors LLC
  3. Janus Henderson Group PLC
  4. Ensign Peak Advisors Inc
  5. Ghisallo Capital Management LLC
  6. Jennison Associates LLC
  7. American Century Companies Inc.

Which institutional investors are buying Centessa Pharmaceuticals stock?

Within the previous quarter, CNTA stock was bought by institutional investors including:
  1. General Atlantic L.P.
  2. RA Capital Management L.P.
  3. Boxer Capital LLC
  4. Point72 Asset Management L.P.
  5. Affinity Asset Advisors LLC
  6. Brookfield Asset Management Inc.
  7. Morgan Stanley
  8. Compagnie Lombard Odier SCmA
Within the previous year, these company insiders have bought Centessa Pharmaceuticals stock:
  1. (Bermuda) Ltd Gap (Major Shareholder)
  2. Aaron Kantoff (Director)
  3. Saurabh Saha (CEO)
  4. Tia L Bush (Insider)
5G Stock CRUSHES Earnings!!
Wall Street is loading up on shares of one 5G SuperStock (with more than $2 billion invested!).

Why?

Because the stock brings in more cash than IBM, Facebook and even Google!

Yet it trades for just under $5.

Get the scoop on the 5G SuperStock right here.
Learn more.